Standard BioTools Inc (LAB) saw an uptrend of 5.43% in the recent trading with $1.94 being its most recent. The current price level -36.18% lower than the highest price of $3.04 marked by the stock while trading over the past 52-weeks, whereas it is 60.33% higher than the lowest price of $1.21 the company dropped to over past 52-weeks. The latest news story on LAB appeared in (GlobeNewswire) under the title “Standard BioTools Appoints Alex Kim as Chief Financial Officer”.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Sponsored
Squeezing the time span to 30 day period shows us the stock is currently trading -16.38% below one month high and is +32.88% above of the lowest during that time. Looking into the simple moving average, Standard BioTools Inc (LAB)’s stock stands at a SMA-50 of $1.8476 while that of 5-day is reading $1.7860.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and LAB’s SMA-200 as of now is $2.1740.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 3 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Standard BioTools Inc Earnings – What Happened With LAB
Coming around sales and income figures on LAB Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Standard BioTools Inc (LAB) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 6.90% for net revenue.
LAB – Standard BioTools Inc Stock Earnings Estimates
The perspective of Standard BioTools Inc (NASDAQ:LAB)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.13 for stock’s EPS in the current quarter. Company’s EPS for the last quarter was -0.12.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 372.26 million. LAB does have institutional investors; and they hold 75.14% of the stock.
Standard BioTools Inc – Insider Activity and Holdings
As on 2024-06-30, CASDIN CAPITAL, LLC was the top most holder in Standard BioTools Inc (NASDAQ:LAB) with an ownership of 63.96 million shares of the company or 17.1782 of the stake worth $113.21 million. The filing also reveals VIKING GLOBAL INVESTORS LP as the second largest holder in the company with a control over 15.7524 of the outstanding shares. Its stake is worth $103.81 million for having 58.65 million shares in hand.
BLACKROCK INC. also came holding a key position in the company during the recent quarter and it now holds 5.8424 of the outstanding shares. With this there are now 188.0 institutions which have possession in LAB’s shares.
Currently, the stock has been recommended as Strong Buy by 3 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Standard BioTools Inc has a debt to equity ratio of 0.18.
Technical Analysis of Standard BioTools Inc (NASDAQ:LAB) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Standard BioTools Inc (LAB), we notice that the stock’s 20-day average volume is at 2,236,055 shares. Medium term indicators at an average of 50% are spotting the stock at Sell with its 50-day average volume of 1,858,162 shares. And to end, LAB’s 100-day average volume is 2,210,003 shares with 50% of the long-term indicators pointing towards Sell for the stock.
